

**Table S3:** Number of events, follow-up time, incidence rates, and hazard ratios for all study outcomes based on a propensity-score matched cohort of 1829 warfarin users and 1829 non-users.

Outcome	Analysis	Exposure group	Number of events	Follow-up time (years)		Incidence rate (per 100 person-years)	Hazard ratio (95% CI)
				Mean ± SD	Median		
<b>All-cause mortality</b>	ITT	Warfarin	760	1.41 ± 1.12	1.14	29.4	0.93 (0.81-1.05)
		No warfarin	773	1.38 ± 1.12	1.07	30.6	
	AT60	Warfarin	331	0.66 ± 0.70	0.41	27.3	0.80 (0.67-0.95)
		No warfarin	641	1.18 ± 1.06	0.86	29.8	
	AT30	Warfarin	233	0.46 ± 0.54	0.26	27.8	0.78 (0.64-0.95)
		No warfarin	641	1.18 ± 1.06	0.86	29.8	
<b>Cardiovascular mortality</b>	ITT	Warfarin	322	1.41 ± 1.12	1.34	12.4	0.90 (0.73-1.10)
		No warfarin	325	1.38 ± 1.12	1.08	12.8	
	AT60	Warfarin	146	0.66 ± 0.70	0.41	12.1	0.82 (0.63-1.08)
		No warfarin	272	1.18 ± 1.06	0.86	12.7	
	AT30	Warfarin	100	0.46 ± 0.54	0.26	11.9	0.82 (0.60-1.13)
		No warfarin	272	1.17 ± 1.06	0.86	12.7	
<b>Ischemic stroke</b>	ITT	Warfarin	49	1.35 ± 1.09	1.07	2.0	0.77 (0.44-1.32)

		No warfarin	47	1.33 ± 1.10	1.03	1.9	
	AT60	Warfarin	24	0.66 ± 0.69	0.41	2.0	1.13 (0.57-2.27)
		No warfarin	41	1.16 ± 1.05	0.84	1.9	
	AT30	Warfarin	18	0.46 ± 0.54	0.25	2.2	1.36 (0.63-2.97)
		No warfarin	41	1.16 ± 1.05	0.84	1.9	
<b>Hemorrhagic stroke</b>	ITT	Warfarin	19	1.37 ± 1.10	1.08	0.7	0.90 (0.37-2.21)
		No warfarin	22	1.35 ± 1.10	1.04	0.9	
	AT60	Warfarin	12	0.66 ± 0.70	0.41	1.0	1.13 (0.46-3.84)
		No warfarin	19	1.17 ± 1.05	0.85	0.9	
	AT30	Warfarin	10	0.46 ± 0.54	0.28	1.2	1.75 (0.51-5.98)
		No warfarin	19	1.17 ± 1.05	0.85	0.9	
<b>Any stroke or stroke death</b>	ITT	Warfarin	85	1.35 ± 1.09	1.06	3.5	0.88 (0.58-1.32)
		No warfarin	86	1.33 ± 1.10	1.02	3.5	
	AT60	Warfarin	45	0.66 ± 0.69	0.41	3.7	1.24 (0.73-2.10)
		No warfarin	72	1.16 ± 1.05	0.84	3.4	
	AT30	Warfarin	35	0.46 ± 0.54	0.25	4.2	1.42 (0.79-2.56)
		No warfarin	72	1.16 ± 1.05	0.84	3.4	
<b>Gastrointestinal bleeding</b>	ITT	Warfarin	96	1.32 ± 1.09	1.02	4.0	1.29 (0.90-1.85)
		No warfarin	90	1.31 ± 1.09	1.00	3.7	

	AT60	Warfarin	55	0.65 ± 0.69	0.40	4.6	1.08 (0.69-1.69)
		No warfarin	77	1.15 ± 1.05	0.83	3.7	
	AT30	Warfarin	44	0.45 ± 0.53	0.25	5.3	1.14 (0.69-1.87)
		No warfarin	77	1.15 ± 1.05	0.83	3.7	
<b>Composite outcome<sup>a</sup></b>	ITT	Warfarin	825	1.29 ± 1.08	1.00	34.8	0.94 (0.83-1.07)
		No warfarin	830	1.29 ± 1.09	0.97	35.2	
	AT60	Warfarin	390	0.65 ± 0.69	0.40	32.9	0.85 (0.72-1.00)
		No warfarin	700	1.13 ± 1.04	0.80	33.8	
	AT30	Warfarin	284	0.45 ± 0.53	0.25	34.4	0.86 (0.72-1.04)
		No warfarin	700	1.13 ± 1.04	0.80	33.8	

AT30 – as treated analyses where patients censored 30 days after drug supply ends, AT60 – as treated where patients censored 60 days after end of drug supply, CI – confidence interval, ITT – intention to treat, SD – standard deviation

<sup>a</sup>Composite outcome includes any stroke or stroke death, gastrointestinal bleeding, and all-cause mortality.